Abstract |
The amino boronic dipeptide, PT-100 ( Val-boro-Pro), a dipeptidyl peptidase (DPP) inhibitor, has been shown to up-regulate gene expression of certain cytokines in hematopoietic tissue via a high-affinity interaction, which appears to involve fibroblast activation protein. Because fibroblast activation protein is also expressed in stroma of lymphoid tissue and tumors, the effect of PT-100 on tumor growth was studied in mice in vivo. PT-100 has no direct cytotoxic effect on tumors in vitro. Oral administration of PT-100 to mice slowed growth of syngeneic tumors derived from fibrosarcoma, lymphoma, melanoma, and mastocytoma cell lines. In WEHI 164 fibrosarcoma and EL4 and A20/2J lymphoma models, PT-100 caused regression and rejection of tumors. The antitumor effect appeared to involve tumor-specific CTL and protective immunological memory. PT-100 treatment of WEHI 164-inoculated mice increased mRNA expression of cytokines and chemokines known to promote T-cell priming and chemoattraction of T cells and innate effector cells. The role of innate activity was further implicated by observation of significant, although reduced, inhibition of WEHI 164 and A20/2J tumors in immunodeficient mice. PT-100 also demonstrated ability to augment antitumor activity of rituximab and trastuzumab in xenograft models of human CD20(+) B-cell lymphoma and HER-2(+) colon carcinoma where antibody-dependent cytotoxicity can be mediated by innate effector cells responsive to the cytokines and chemokines up-regulated by PT-100. Although CD26/DPP-IV is a potential target for PT-100 in the immune system, it appeared not to be involved because antitumor activity and stimulation of cytokine and chemokine production was undiminished in CD26(-/-) mice.
|
Authors | Sharlene Adams, Glenn T Miller, Michael I Jesson, Takeshi Watanabe, Barry Jones, Barbara P Wallner |
Journal | Cancer research
(Cancer Res)
Vol. 64
Issue 15
Pg. 5471-80
(Aug 01 2004)
ISSN: 0008-5472 [Print] United States |
PMID | 15289357
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Agents
- Boronic Acids
- Chemokines
- Cytokines
- Dipeptides
- Enzyme Inhibitors
- Neoplasm Proteins
- PT-100 dipeptide
- Rituximab
- Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
- Dipeptidyl Peptidase 4
- Trastuzumab
|
Topics |
- Administration, Oral
- Animals
- Antibodies, Monoclonal
(administration & dosage)
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal, Murine-Derived
- Antibody-Dependent Cell Cytotoxicity
(immunology)
- Antineoplastic Agents
(therapeutic use)
- Boronic Acids
(therapeutic use)
- Chemokines
(metabolism)
- Colonic Neoplasms
(drug therapy, pathology)
- Cytokines
(metabolism)
- Dipeptides
(therapeutic use)
- Dipeptidyl Peptidase 4
(metabolism)
- Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
(antagonists & inhibitors)
- Enzyme Inhibitors
(pharmacology)
- Fibrosarcoma
(drug therapy, pathology)
- Gene Expression Profiling
- Humans
- Lymphoma
(drug therapy, pathology)
- Mastocytoma
(drug therapy, pathology)
- Melanoma
(drug therapy, pathology)
- Mice
- Mice, Inbred BALB C
- Mice, Inbred C57BL
- Mice, Inbred DBA
- Mice, Inbred NOD
- Mice, Knockout
- Neoplasm Proteins
(metabolism)
- Neoplasms, Experimental
(drug therapy, pathology)
- Oligonucleotide Array Sequence Analysis
- Rituximab
- Transplantation, Heterologous
- Trastuzumab
|